Research
<<Back to Main Research Page
Pharmacotherapy for cognitive impairment in a mouse
model of Down syndrome.
• Fernandez F,
• Morishita W,
• Zuniga E,
• Nguyen J,
• Blank M,
• Malenka RC,
• Garner CC.
Department of Psychiatry and Behavioral Sciences, Nancy
Pritzker Laboratory, Stanford University, Palo Alto, California
94304-5485, USA.
Ts65Dn mice, a model for Down syndrome, have excessive inhibition
in the dentate gyrus, a condition that could compromise synaptic
plasticity and mnemonic processing. We show that chronic systemic
treatment of these mice with GABAA antagonists at non-epileptic
doses causes a persistent post-drug recovery of cognition
and long-term potentiation. These results suggest that over-inhibition
contributes to intellectual disabilities associated with Down
syndrome and that GABAA antagonists may be useful therapeutic
agents for this disorder.
PMID: 17322876 [PubMed - in process]
<<Back to Main Research Page
 __________________________________________________________
|
